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sources for human biology and disease
research and the potential for developing
gene and cell therapy. Realization of this
potential will rely in part on our ability to
precisely edit or engineer the human
genome in an efficient way. Recent devel-
opments in designer endonuclease tech-
nologies such as zinc finger nuclease
(ZFN), transcription activator-like effector
nuclease (TALEN), and clustered regula-
tory interspaced short palindromic repeat
(CRISPR)/Cas9 endonuclease have pro-
vided ways to significantly improve
genome editing efficiency in human
iPSCs. These endonucleases make a
double-stranded break (DSB) at a pre-
determined DNA sequence and trigger
natural DNA repair processes such as
nonhomologous end joining (NHEJ) or
homologous recombination (HR) with a
donor DNA template. Among these exist-
ing approaches, RNA-guided CRISPR/
Cas9 is the most user-friendly and versa-
tile system, and it has been applied in
both animal models and cell lines (Cong
et al., 2013; Hsu et al., 2014; Mali et al.,
2013). The most commonly used system
consists of a single polypeptide endo-
nuclease Cas9 complexed with a single
guide RNA (gRNA) that provides comple-
mentarity to 20-nucleotide target DNA
sequence. However, the specificity and
efficiency of this approach in human
iPSCs have not been studied in detail
(Cong et al., 2013; Ding et al., 2013; Mali
et al., 2013; Yang et al., 2013). Some ana-
lyses using cancer cell lines reported
higher-than-expected levels of off-target
mutagenesis by Cas9-gRNAs (Fu et al.,12 Cell Stem Cell 15, July 3, 2014 ª2014 Else2013; Hsu et al., 2013), raising concerns
about the practical applicability of this
approach in therapeutic contexts. Some
recent studies, including one on human
adult stem cells, showed a minimal level
of off-target effects by CRISPR/Cas9
(Schwank et al., 2013). However, these
existing analyses of off-target effects
and mutational load in gene-corrected
stem cells have been restricted to check-
ing predicted off target sites and are
therefore limited in scope. To assess
the value of this type of gene editing
approach for therapeutic applications, it
is critical to rigorously examine whether
it is possible to generate gene-edited
cell lines with minimal mutational load.
To this end, we have conducted whole-
genome sequencing of four iPSC clones
successfully targeted at the AAVS1 locus,
a ‘‘safe harbor’’ in the human genome that
is used for stable transgene expression in
a variety of contexts. To generate the
lines, we used an integration-free human
iPSC line, BC1, whose genomic integrity
has been characterized in detail by next-
generation sequencing (Cheng et al.,
2012) and targeted a GFP expression
cassette into the AAVS1 site with either
a previously reported Cas9-gRNA combi-
nation or a pair of improved heterodimeric
TALENs (Mali et al., 2013; Yan et al., 2013)
(Table S1 and Supplemental Experi-
mental Procedures available online).
Twenty days after transfection of the
donor plasmid and either the TALENs or
Cas9-gRNA into BC1, we harvested four
clones with confirmed targeted integra-
tion (hCas9-C4, hCas9-C16, TALEN-C3,
and TALEN-C6; Table S1 and Supple-vier Inc.mental Experimental Procedures) and
the parental BC1 iPSCs for whole-
genome sequencing. The sequencing
reads, ranging from 83 Gbps to 100
Gbps from each targeted clone, were first
aligned to the human hg19 reference
genome to enable identification of sin-
gle-nucleotide variants (SNVs) and small
indels (Table S1). Our analysis identi-
fied R4.2 million SNVs and R500,000
indels in each genome (Table S1) in com-
parison to the hg19 reference genome,
suggesting that it is a rigorous data set
that covers the genome in sufficient depth
to detect sequence variants. The ‘‘germ-
line’’ variants (present in BC1 parental
iPSCs and different from hg19) were
readily detectable in each targeted cell
line (80%%–88%), indicating that the
sensitivity of variant detection in our anal-
ysis is high (Table S1). The variations from
each targeted clone were then compared
to the BC1 parental iPSCs to enable the
generation of a list of potential variations
arising during the gene editing pro-
cess, which we then confirmed using
genomic PCR and Sanger sequencing.
We confirmed 62 out of 69 SNVs tested
for an overall confirmation rate of 90%,
and based on that we estimate that the
total SNVs in the four iPSC clones range
between 217 and 281 and that the total
indels range between 7 and 12 (Table
S1). Overall the genomic variation levels
in TALEN- and Cas9-targeted groups
were comparable. One important consid-
eration is how many of these detected
SNVs and indels were the results of off-
target mutagenesis by the engineered en-
donucleases. To address this question,
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Letterwe generated a list of 3,665 (Cas9) and
238 (TALEN) putative off-target positions
by using the EMBOSS fuzznuc software
package. Each candidate SNV and indel
was compared to this list and none of
them are within a potential off-target re-
gion (Table S1), consistent with previous
analyses looking at predicted off-target
sites. Our analysis also shows that each
SNV and indel is unique and that none of
them occurred in more than one cell line.
The absence of recurring mutations
and the fact that none of the mutations
resides in any putative off-target site
by bioinformatic prediction strongly sug-
gest that these mutations were randomly
accumulated during regular cell expan-
sion and are not direct results of off-target
activities by Cas9 or TALENs.
Our results from whole-genome
sequencing analysis of Cas9- and
TALEN-targeted human iPSC clones
demonstrate that these engineered endo-
nucleases provide efficient genome-edit-
ing tools with high specificity. It remains
tobe clarifiedwhether the higher off-target
rates observed in cancer cell lines are
due to the overexpression of gRNAs and
Cas9 protein and/or due to exacerbated
and faulty DNA repair in these cell types.
The higher specificity observed in human
iPSCs, combined with the rapid develop-ment of next-generation sequencing tech-
nology, makes it possible to characterize
and isolate high quality genome-edited
stem cell clones with minimal mutational
load. The guiding principle established
with human iPSCs will likely be applicable
to other types of stem cells and comewith
improvements in gene transfer and target-
ing efficiencies. Our current study of gene
targeting in human iPSCs will help to
establish better models for human biology
and disease research and to provide
proof-of-principle for future gene therapy.
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